Allogene Therapeutics Inc. (NASDAQ:ALLO) saw an upside of 15.74% to close Tuesday at $7.94 after adding $1.08 on the day. The 5-day average trading volume is 2,067,680 shares of the company’s common stock. It has gained $8.10 in the past week and touched a new high 2 times within the past 5 days. An average of 1,951,855 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,036,220.
ALLO’s 1-month performance is 27.04% or $1.98 on its low of $5.41 reached on 01/05/23. The company’s shares have touched a 52-week low of $5.41 and high of $17.49, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, ALLO has achieved 26.23% or $1.65 and has reached a new high 5 times. However, the current price is down -54.60% from the 52-week high price.
ALLO stock investors last saw insider trading activity on Jan 17.Bhavnagri Veer (General Counsel) most recently sold 3,000 shares at $7.04 per share on Jan 17. This transaction cost the insider $21,120. General Counsel, Bhavnagri Veer, sold 5,602 shares at a price of $7.53 on Dec 15. Then, on Aug 12, Director WITTE OWEN N. sold 5,000 shares at a price of $17.25 per share. This transaction amounted to $86,250.
ALLO stock has a beta of 0.71. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5567.53 while the price-to-book (PB) in the most recent quarter is 1.54.
Allogene Therapeutics Inc.’s quick ratio for the period ended September 29 was 11.60, with the current ratio over the same period at 11.60. The firm’s gross profit as reported stood at $294.28 million against revenue of $38.49 million.
For the quarterly period ending September 29 this year, Allogene Therapeutics Inc.’s cash and short-term investments amounted to $477.87 million against total debt of $102.54 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 5.97% to -$83.15 million, while revenue of -$74.79 million was 10.05% off the previous quarter. Analysts expected ALLO to announce -$0.64 per share in earnings in its latest quarter, but it posted -$0.58, representing a 9.40% surprise. EBITDA for the quarter stood at more than -$78.13 million. ALLO stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 147.61 million, with total debt at $102.54 million. Shareholders hold equity totaling $144.21 million.
Let’s look briefly at Allogene Therapeutics Inc. (ALLO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 72.19% to suggest the stock is trending Overbought, with historical volatility in this time period at 91.61%.
The stock’s 5-day moving average is $6.84, reflecting a +14.24% or $0.99 change from its current price. ALLO is currently trading +31.24% above its 20-day SMA, -41.70% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -9.36% and SMA200 by-16.24%.
Stochastic %K and %D was 75.46% and 63.21% and the average true range (ATR) pointed at 0.59. The RSI (14) points at 62.30%, while the 14-day stochastic is at 94.06% with the period’s ATR at 0.58. The stock’s 9-day MACD Oscillator is pointing at 0.26 and 0.58 on the 14-day charts.
In the most recent analyst report for Allogene Therapeutics Inc. (NASDAQ: ALLO), JP Morgan upgraded it to an Overweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for ALLO stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate ALLO as a “sell,”, while 3 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 1 rates the stock as overweight while 14 have offered a “buy” rating.
What is ALLO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $55.00, with their median price target at $17.00. Looking at these predictions, the average price target given by analysts is for Allogene Therapeutics Inc. (ALLO) stock is $22.00.